Literature DB >> 3922270

The equivalency of two L-thyroxine preparations.

J V Hennessey, K D Burman, L Wartofsky.   

Abstract

Differences in blood levels of thyroid hormones have been reported when patients taking synthetic L-thyroxine were shifted from one manufactured form of the hormone to another. Because recent formulation changes have rendered these earlier data obsolete, we did a crossover study to determine differences in bioavailability of the two principal brands of thyroxine, Synthroid and Levothroid. Twenty patients received Synthroid and then Levothroid, and 14 received Levothroid and then Synthroid. Patients received each drug for 6 weeks. Although no significant differences were seen in routine thyroid hormone measurements, combined data from both groups showed a significantly higher free thyroxine level in the patients treated with Synthroid, as well as lower thyrotrophin values at 15 and 30 minutes after administration of thyrotrophin-releasing hormone. Equal doses of the currently manufactured forms of these two products are similar but not bioequivalent.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922270     DOI: 10.7326/0003-4819-102-6-770

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 2.  The emergence of levothyroxine as a treatment for hypothyroidism.

Authors:  James V Hennessey
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

3.  Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures.

Authors:  Ingeborg Walter-Sack; Christof Clanget; Reinhard Ding; Christoph Goeggelmann; Vera Hinke; Matthias Lang; Johannes Pfeilschifter; Yorki Tayrouz; Karl Wegscheider
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  [Bioequivalence of a combination of levothyroxine and iodine in comparison with levothyroxine only. A controlled double-blind study of bioavailability].

Authors:  G Förster; C Hansen; F Mörsch; K al-Hakim; J Beyer; G Kahaly
Journal:  Med Klin (Munich)       Date:  1998-07-15

Review 5.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

6.  TSH-based protocol, tablet instability, and absorption effects on L-T4 bioequivalence.

Authors:  Marisa Eisenberg; Joseph J Distefano
Journal:  Thyroid       Date:  2009-02       Impact factor: 6.568

Review 7.  Thyroxine and treatment of hypothyroidism: seven decades of experience.

Authors:  Roselyn Cristelle I Mateo; James V Hennessey
Journal:  Endocrine       Date:  2019-07-18       Impact factor: 3.633

8.  Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products.

Authors:  Gopal Pawar; Fang Wu; Liang Zhao; Lanyan Fang; Gilbert J Burckart; Kairui Feng; Youssef M Mousa; Franci Naumann; Hannah K Batchelor
Journal:  AAPS J       Date:  2021-04-21       Impact factor: 4.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.